表紙:急性骨髄性白血病:現在および今後の市場機会、疫学調査、市場力学、パイプライン分析、r-NPV分析
市場調査レポート
商品コード
1024215

急性骨髄性白血病:現在および今後の市場機会、疫学調査、市場力学、パイプライン分析、r-NPV分析

Acute Myeloid Leukemia - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版日: | 発行: GervanoRA Data Services LLP | ページ情報: 英文 250 Pages | 納期: 3~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.72円
急性骨髄性白血病:現在および今後の市場機会、疫学調査、市場力学、パイプライン分析、r-NPV分析
出版日: 2021年08月16日
発行: GervanoRA Data Services LLP
ページ情報: 英文 250 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、急性骨髄性白血病について調査しており、疫学調査、市場規模や予測、KOLの洞察を活用した新規参入企業の価格戦略、リスク調整正味現在価値(RNPV)分析、パイプラインの洞察とベンチマークのスナップショット、競合情勢、アンメットニーズや機会などの情報を提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 急性骨髄性白血病の概要と疫学調査

第4章 急性骨髄性白血病の市場売上:現在と予測(2020-2030)

第5章 パイプラインの洞察とベンチマークの見通し

第6章 急性骨髄性白血病の競合空間の取引活動

第7章 急性骨髄性白血病パイプライン薬の比較特許分析

第8章 リスク調整正味現在価値(R-NPV)分析

第9章 競合機会の評価

図表

LIST OF TABLES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: GLOBAL AML EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 03: US AML EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 04: UK AML EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 05: AML GLOBAL CURRENT MARKET (2020), FORECAST (2021-2030)
  • TABLE 06: AML US CURRENT MARKET (2020), FORECAST (2021-2030)
  • TABLE 07: COMPARISON OF AML MARKET VALUES GLOBAL VERSUS US (2020-2030)(M$)
  • TABLE 08: PHASE 3 MOLECULES IN AML DRUG PIPELINE
  • TABLE 09: PHASE 2 MOLECULES IN AML DRUG PIPELINE
  • TABLE 10: PHASE 1 MOLECULES IN AML DRUG PIPELINE
  • TABLE 11: PRECLINICAL MOLECULES IN AML DRUG PIPELINE
  • TABLE 12: EARLY R&D MOLECULES IN AML DRUG PIPELINE
  • TABLE 13: AML PIPELINE ANALYTICS BY COMPANY TYPE
  • TABLE 14: MAJOR MERGERS AND ACQUISITIONS IN AML THERAPEUTIC AREA
  • TABLE 15: MAJOR COLLABORATIVE AGREEMENTS IN AML THERAPEUTIC AREA
  • TABLE 16: MAJOR LICENSING AGREEMENTS IN AML THERAPEUTIC AREA
  • TABLE 17: MAJOR FINANCING AGREEMENTS IN AML THERAPEUTIC AREA
  • TABLE 18: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN AML THERAPEUTIC AREA
  • TABLE 19: COMPANIES LOOKING FOR CORPORATE PARTNERING, LICENSING, FUNDING OPPORTUNITIES
  • TABLE 20: COMPANIES DEVELOPING PIPELINE ASSETS ON THEIR OWN

LIST OF FIGURES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN AML COMPETITIVE AREA
  • FIGURE 02: GLOBAL AML POPULATION (2020) FORECAST (2021-2030), IN MILLION
  • FIGURE 03: US AML POPULATION (2020) FORECAST (2021-2030), IN MILLION
  • FIGURE 04: US CURRENT (2020) AML MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 05: OVERALL DEALS ACTIVITY IN AML THERAPEUTIC AREA SINCE 2010
  • FIGURE 06: AML PIPELINE DRUGS WITH RESPECT TO STAGES OF DEVELOPMENT
  • FIGURE 07: AML PIPELINE ANALYTICS BY ROA
  • FIGURE 08: AML PIPELINE ANALYTICS BY DRUG CLASS
  • FIGURE 09: AML PIPELINE ANALYTICS BY MECHANISM OF ACTION
  • FIGURE 10: AML PIPELINE ANALYTICS BY COMPANY TYPE
目次
Product Code: GERPH516

GervanoRA's pipeline analysis and opportunity assessment report "Acute Myeloid Leukemia - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Acute Myeloid Leukemia pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Acute Myeloid Leukemia drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Acute Myeloid Leukemia area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Acute Myeloid Leukemia drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Acute Myeloid Leukemia historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Acute Myeloid Leukemia Market (2020) and the Forecasted Acute Myeloid Leukemia Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Acute Myeloid Leukemia Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Acute Myeloid Leukemia Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Acute Myeloid Leukemia Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: ACUTE MYELOID LEUKEMIA OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: ACUTE MYELOID LEUKEMIA CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF ACUTE MYELOID LEUKEMIA COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF ACUTE MYELOID LEUKEMIA PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS